Takeda Gains On Sanofi As Two-Shot Dengue Vaccine Advances

While Sanofi late last year became the first company to commercialize a vaccine for dengue, Takeda has strengthened its position as the likely next to market contender following the start of a global Phase III program for its rival product.

Zika Mosquito

More from R&D

More from Scrip